# Introduction to Clinical Trials - Day 2

Session 2 - Surrogate Endpoints

Presented July 26, 2016

Susanne J. May Department of Biostatistics University of Washington

Daniel L. Gillen Department of Statistics University of California, Irvine Choice of a Primary Outcome Clinical Endpoints Multiple Endpoints and

Competing Risks

SISCR UW - 2016

Surrogate Endpoints Motivation and Examples Examples of Problems with Surrogates Ideal Surrogate Alternate Pathways Surrogate Markers Examples Revisited HIV Meta-Analysis CAST CGD

Validation of Surrogate Outcomes Prentice's Criteria

SISCR - RCT, Day 2 - 2 : 1

©2016 Daniel L. Gillen, PhD and Susanne J. May, PhD

### Choice of a Primary Outcome

Importance of primary outcome specification

- The goal of a RCT is to find effective treatment indications
  - The primary outcome is a crucial element of the indication
- ► Scientific basis:
  - A clinical trial is planned to detect the effect of a treatment on some outcome
  - Statement of the outcome is a fundamental part of the scientific hypothesis
- Ethical basis:
  - Generally, subjects participating in a clinical trial are hoping that they will benefit in some way from the trial
  - Clinical endpoints are therefore of more interest than purely biological endpoints

## SISCR UW - 2016

Choice of a Primary Outcome Clinical Endpoints Multiple Endpoints and Competing Risks

Surrogate Endpoints Motivation and Examples Examples of Problems with Surrogates Ideal Surrogate Alternate Pathways Surrogate Markers Examples Revisited HIV Meta-Analysis CAST CGD

Validation of Surrogate Outcomes Prentice's Criteria

SISCR - RCT, Day 2 - 2 :2

#### **Choice of a Primary Outcome** SISCR **UW - 2016** Multiple comparison issues Choice of a Primary Type I error for each endpoint Outcome **Clinical Endpoints** Multiple Endpoints and Competing Risks In absence of treatment effect, will still decide a benefit Surrogate Endpoints exists with probability, say, .025 Motivation and Examples Examples of Problems with Surrogates Ideal Surrogate Multiple endpoints increase the chance of deciding an Alternate Pathways Surrogate Markers ineffective treatment should be adopted: Examples Revisited HIV Meta-Analysis CAST This problem exists with either frequentist or Bayesian CGD Validation of Surrogate criteria for evidence Outcomes Prentice's Criteria The actual inflation of the type I error depends on 1. the number of multiple comparisons, and 2. the correlation between the endpoints SISCR - RCT, Day 2 - 2 :3 **Choice of a Primary Outcome** SISCR **UW - 2016 Multiple comparison issues**

 Ex: Consider experiment-wise error rate when using level .05 per decision

Number	Worst	Correlation					
Compared	Case	0.00	0.30	0.50	0.75	0.90	
1	.050	.050	.050	.050	.050	.050	
2	.100	.098	.095	.090	.081	.070	
3	.150	.143	.137	.126	.104	.084	
5	.250	.226	.208	.184	.138	.101	
10	.500	.401	.353	.284	.193	.127	
20	1.000	. 642	.540	.420	.258	.154	
50	1.000	. 923	.806	. 624	.353	.193	

Choice of a Primary Outcome Clinical Endpoints Multiple Endpoints and Competing Risks

Surrogate Endpoints Motivation and Examples Examples of Problems with Surrogates Ideal Surrogate Alternate Pathways Surrogate Markers Examples Revisited HIV Meta-Analysis CAST CGD

### **Choice of a Primary Outcome**

#### **Primary endpoint: Clinical**

- Should consider (in order of importance)
  - The most relevant clinical endpoint (Survival, quality of life)
  - The endpoint the treatment is most likely to affect
  - The endpoint that can be assessed most accurately and precisely

#### SISCR - RCT, Day 2 - 2 : 5

### **Choice of a Primary Outcome**

### **Additional Endpoints**

- Other outcomes are then relegated to a "secondary" status
  - Supportive and confirmatory
  - Safety
- Some outcomes are considered "exploratory"
  - Subgroup effects
  - Effect modification

## SISCR UW - 2016

Choice of a Primary Outcome

Clinical Endpoints Multiple Endpoints and Competing Risks

Surrogate Endpoints Motivation and Examples

Examples of Problems with Surrogates Ideal Surrogate Alternate Pathways Surrogate Markers Examples Revisited HIV Meta-Analysis CAST CGD

Validation of Surrogate Outcomes Prentice's Criteria

### SISCR UW - 2016

Choice of a Primary Outcome Clinical Endpoints

Multiple Endpoints and Competing Risks


Surrogate Endpoints Motivation and Examples Examples of Problems with Surrogates

Ideal Surrogate Alternate Pathways Surrogate Markers

Outcomes Prentice's Criteria


Examples Revisited HIV Meta-Analysis CAST CGD

Validation of Surrogate



- Must show improvement in treatment group on all endpoints
- No guarantee that the same subjects are experiencing the improvement

SISCR - RCT, Day 2 - 2 :8



### **Choice of a Primary Outcome**

#### Issues with clinical outcomes

- Goal of clinical trial is to establish whether an experimental treatment will prevent a particular clinical outcome
  - Incidence of disease
  - Decreased quality of life
  - Mortality
- Relevant clinical outcomes are often relatively rare events that occur after a significant delay
  - Believe that earlier interventions have greater chance of benefit
- It can also be logistically difficult to measure a clinical outcome
  - Quality of life needs to be assessed over a sufficiently long period of time

### SISCR UW - 2016

Choice of a Primary Outcome Clinical Endpoints Multiple Endpoints and Competing Risks

Surrogate Endpoints Motivation and Examples Examples of Problems with Surrogates Ideal Surrogate Alternate Pathways Surrogate Markers Examples Revisited HIV Meta-Analysis CAST CGD

Validation of Surrogate Outcomes Prentice's Criteria

SISCR - RCT, Day 2 - 2 :11

### **Choice of a Primary Outcome**

#### Impact on trial design

- Large sample size required to assess treatment effect on rare events
- Long period of follow-up needed to assess endpoints
- Isn't there something else that we can do?
- A tempting alternative is to move to "surrogate" endpoints...

## SISCR UW - 2016

Choice of a Primary Outcome Clinical Endpoints Multiple Endpoints and Competing Risks

Surrogate Endpoints Motivation and Examples Examples of Problems with Surrogates Ideal Surrogate Alternate Pathways Surrogate Markers Examples Revisited HIV Meta-Analysis CAST CGD

#### Surrogate Endpoints SISCR **UW - 2016** Choice of a Primary Motivation for surrogate endpoints Outcome Clinical Endpoints Multiple Endpoints and Competing Risks Hypothesized role of surrogate endpoints Surrogate Endpoints Motivation and Examples Examples of Problems with Find a biological endpoint which Surrogates Ideal Surrogate Alternate Pathways can be measured in a shorter timeframe, Surrogate Markers Examples Revisited can be measured precisely, and HIV Meta-Analysis is predictive of the clinical outcome CAST CGD Validation of Surrogate Use of such an endpoint as the primary measure of Outcomes treatment effect will result in more efficient trials. Prentice's Criteria SISCR - RCT, Day 2 - 2 :13 **Surrogate Endpoints** SISCR **UW - 2016** Choice of a Primary Outcome Clinical Endpoints Identifying potential surrogates Multiple Endpoints and Competing Risks Surrogate Endpoints Typically use observational data to find risk factors for Motivation and Examples Examples of Problems with clinical outcome Surrogates Ideal Surrogate Alternate Pathways Surrogate Markers Treatments attempt to intervene on those risk factors Examples Revisited HIV Meta-Analysis CAST CGD Surrogate endpoint for the treatment effect is then a Validation of Surrogate change in the risk factor Outcomes Prentice's Criteria

### **Surrogate Endpoints**

#### **Examples of surrogates**

- Colon cancer prevention
  - Two-fold increase in risk of colon cancer for patients with adenomatous colon polyps
  - Prevention directed toward preventing colon polyps
  - Treatment effect measured by decreased incidence of colon polyps
  - True clinical outcome is preventing mortality

### SISCR - RCT, Day 2 - 2 :15

### Surrogate Endpoints

#### Examples of surrogates

- ► HIV/AIDS
  - HIV leads to suppression of CD4 cells
  - Decreased CD4 levels correlates with development of AIDS
  - Treatment effects measured by following CD4 counts
  - True clinical outcome is prevention of morbidity and mortality

### SISCR UW - 2016

Choice of a Primary Outcome Clinical Endpoints Multiple Endpoints and Competing Risks

#### Surrogate Endpoints Motivation and Examples

Examples of Problems with Surrogates Ideal Surrogate Alternate Pathways Surrogate Markers Examples Revisited HIV Meta-Analysis CAST CGD

Validation of Surrogate Outcomes Prentice's Criteria

### SISCR UW - 2016

Choice of a Primary

Surrogate Endpoints Motivation and Examples Examples of Problems with

Outcome Clinical Endpoints Multiple Endpoints and Competing Risks

Surrogates

Ideal Surrogate Alternate Pathways Surrogate Markers Examples Revisited

HIV Meta-Analysis CAST CGD

Outcomes Prentice's Criteria

Validation of Surrogate

SISCR - RCT, Day 2 - 2 :16

### **Surrogate Endpoints**

#### **Examples of surrogates**

- Coronary heart disease
  - Poor prognosis in patients with arrhythmias following heart attack
  - Therapies directed toward preventing arrhythmias
  - Treatment effects measured by prevention of arrhythmias
  - True clinical outcome is prevention of mortality

SISCR - RCT, Day 2 - 2 :17

### **Surrogate Endpoints**

#### **Examples of surrogates**

- Liver failure
  - Poor prognosis in patients who develop renal failure
  - Therapies directed toward treating renal failure (dialysis)
  - Treatment effects measured by creatinine, BUN
  - True clinical outcome is prevention of mortality

### SISCR UW - 2016

Choice of a Primary Outcome Clinical Endpoints Multiple Endpoints and Competing Risks

#### Surrogate Endpoints Motivation and Examples

Examples of Problems with Surrogates Ideal Surrogate Alternate Pathways Surrogate Markers Examples Revisited HIV Meta-Analysis CAST CGD

Validation of Surrogate Outcomes Prentice's Criteria

### SISCR UW - 2016

Choice of a Primary Outcome

Surrogate Endpoints Motivation and Examples Examples of Problems with

Clinical Endpoints Multiple Endpoints and Competing Risks

Surrogates Ideal Surrogate

Alternate Pathways Surrogate Markers Examples Revisited

HIV Meta-Analysis CAST CGD

### **Surrogate Endpoints**

### **Examples of surrogates**

- Other examples that have been used historically include
  - Cancer: tumor shrinkage
  - Coronary heart disease: cholesterol, nonfatal MI, blood pressure
  - Congestive heart failure: cardiac output
  - Arrhythmia: atrial fibrillation
  - Osteoporosis: bone mineral density
- Future surrogates?
  - Gene expression
  - Proteomics

### **Surrogate Endpoints**

### **Problem with surrogates**

- Establishing biologic activity does not always translate into effects on the clinical outcome
- May be treating the symptom, not the disease
  - ► Concorde: ZDV improves CD4, not survival
  - CAST: encainide, flecainide prevents arrhythmias, worsens survival
- May be missing effect through other pathways
  - Intl CGD group: Gamma-INF no affect on biomarkers, decreases serious infections

### SISCR UW - 2016

Choice of a Primary Outcome Clinical Endpoints Multiple Endpoints and Competing Risks

Surrogate Endpoints

Motivation and Examples Examples of Problems with Surrogates Ideal Surrogate Alternate Pathways Surrogate Markers Examples Revisited HIV Meta-Analysis CAST CGD

Validation of Surrogate Outcomes Prentice's Criteria


SISCR - RCT, Day 2 - 2 :19

### SISCR UW - 2016

Choice of a Primary Outcome Clinical Endpoints Multiple Endpoints and Competing Risks


Surrogate Endpoints Motivation and Examples


Examples of Problems with Surrogates Ideal Surrogate Alternate Pathways Surrogate Markers Examples Revisited HIV Meta-Analysis CAST CGD





Examples of Problems with Ex: Concorde Trial (Lancet, 1	SISCR UW - 2010		
<ul> <li>However, more deaths equal 3-year survival ra</li> </ul>	Choice of a Primary Outcome Clinical Endpoints Multiple Endpoints and Competing Risks		
AIDS / Death Death	ZDV (n = 877) 175 95	Placebo (n = 872) 171 76	Surrogate Endpoints Motivation and Examples Examples of Problems with Surrogates Ideal Surrogate Alternate Pathways Surrogate Markers Examples Revisited HIV Meta-Analysis CAST CGD
3 year survival	92%	93%	Validation of Surrogate Outcomes Prentice's Criteria
therapy on disease progress	sion and surviva	l."	SISCR - RCT, Day 2 - 2 :23
Ex: HIV Meta-Analysis			
<ul> <li>Ex: HIV Meta-Analysis</li> <li>Ex: HIV Meta-analysis</li> <li>Review of ZDV, ddl and Clinical Endpoints</li> <li>16 trials reviewed by</li> </ul>	-		d Choice of a Primary Outcome Clinical Endpoints Multiple Endpoints and Competing Risks Surrogate Endpoints Motivation and Examples Examples of Problems with Surrogates
<ul> <li>Ex: HIV Meta-analysis</li> <li>▶ Review of ZDV, ddl and Clinical Endpoints</li> </ul>	NIAID S.O.T.A. P		d Choice of a Primary Outcome Clinical Endpoints Multiple Endpoints and Competing Risks Surrogate Endpoints Motivation and Examples Examples of Problems with
<ul> <li>Ex: HIV Meta-analysis</li> <li>Review of ZDV, ddl and Clinical Endpoints</li> <li>16 trials reviewed by AIDS/E</li> </ul>	NIAID S.O.T.A. P	anel, Jun 93 Survival ? S 3 2	d Choice of a Primary Outcome Clinical Endpoints Multiple Endpoints and Competing Risks Surrogate Endpoints Motivation and Examples Examples of Problems wit Surrogates Ideal Surrogate Alternate Pathways Surrogate Markers Examples Revisited HIV Meta-Analysis CAST


#### **Ex: CAST** SISCR **UW - 2016** Choice of a Primary Ex: Cardiac Arrhythmia Suppression Trial (CAST) Outcome Clinical Endpoints Multiple Endpoints and Arrhythmia a risk factor for sudden death following a Competing Risks myocardial infarction Surrogate Endpoints Motivation and Examples Examples of Problems with Surrogates Antiarrhythmic drugs (encainide and flecainide) Ideal Surrogate Alternate Pathways successfully decrease incidence of arrhythmias Surrogate Markers Examples Revisited HIV Meta-Analysis CAST CAST CGD Validation of Surrogate Outcomes Placebo controlled trial using mortality as outcome Prentice's Criteria Encainide and flecainide TRIPLE the death rate SISCR - RCT, Day 2 - 2 :25 Ex: CGD SISCR **UW - 2016** Choice of a Primary Ex: Chronic Granulomatous Disease (CGD) Outcome Clinical Endpoints Multiple Endpoints and Competing Risks CGD leads to recurrent serious infections Surrogate Endpoints Motivation and Examples Examples of Problems with Gamma interferon increases bacterial killing and Surrogates Ideal Surrogate superoxide production? Alternate Pathways Surrogate Markers Examples Revisited HIV Meta-Analysis International CGD Study Group Trial of Gamma-INF CAST CGD Validation of Surrogate 70% reduction in recurrent serious infections Outcomes Prentice's Criteria Essentially no effect on biological markers





























### Validation of Surrogate Outcomes

### What doesn't work...

Consider the following hypothetical example

	Treatment		Control	
Surrogate	n	% die	n	% die
Low	30	50%	10	30%
Medium	40	60%	30	40%
High	30	70%	60	50%
Total	100	60%	100	45%

### SISCR UW - 2016

Choice of a Primary Outcome Clinical Endpoints Multiple Endpoints and Competing Risks

Surrogate Endpoints Motivation and Examples Examples of Problems with Surrogates Ideal Surrogate Alternate Pathways Surrogate Markers Examples Revisited HIV Meta-Analysis CAST CGD

Validation of Surrogate Outcomes Prentice's Criteria

SISCR - RCT, Day 2 - 2 :49

### Validation of Surrogate Outcomes

### **Ex: CARET**

- Beta-carotene supplementation for prevention of cancer in smokers
- Treatment group had excess cancer incidence and death
- Within each group, subjects having higher beta-carotene levels in their diet had better survival

### SISCR UW - 2016

Choice of a Primary Outcome Clinical Endpoints Multiple Endpoints and Competing Risks

Surrogate Endpoints Motivation and Examples Examples of Problems with Surrogates Ideal Surrogate Alternate Pathways Surrogate Markers Examples Revisited HIV Meta-Analysis CAST CGD

